Hsiu J. Ho
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Hsiu J. Ho has a total of 51 co-authors. Here are the top co-authors by number of shared publications:
- Chun-Ying Wu
Faculty of Medicine and Institute of Clinical Medicine, National Yang Ming Chiao Tung University
4 shared publications - An K. Le
Department of Pharmaceutical Sciences, School of Pharmacy, University of Pittsburgh, Pittsburgh, PA 15213, USA
1 shared publication - Anna Sf Lok
Department of Internal Medicine, Division of Gastroenterology and Hepatology, University of Michigan, Ann Arbor, Michigan, USA
1 shared publication - Bin Wei
School of Life Sciences, Shanghai University, Shanghai 200444, China
1 shared publication - Biyao Zou
Division of Gastroenterology and Hepatology, Stanford University Medical Center, Palo Alto, California, USA
1 shared publication - Carmen Monica Preda
Faculty of Medicine, “Carol Davila” University of Medicine and Pharmacy, 050474 Bucharest, Romania
1 shared publication
Latest Publications
- Open Access
- 12 January 2026
- Published by S. Karger AG in Liver Cancer
- p. 1-12
Dynamic FIB-4 Score Changes and HCC Risk in Patients with MASLD and Elevated Liver Enzymes: A Nationwide Cohort Study
Introduction: Hepatocellular carcinoma (HCC) can develop in individuals with metabolic dysfunction-associated steatotic liver disease (MASLD) without cirrhosis, especially in those with elevated liver enzymes. However, there is currently no low-cost, scalable screening tool for this population. To address this need, we investigated the association between serial changes in FIB-4 (fibrosis-4) scores over a 3-year period and the risk of developing HCC in a large, diverse cohort of patients with MASLD without cirrhosis. Methods: This study utilized a nationwide cohort from the National Health Insurance Research Database (NHIRD), including 810,698 patients with MASLD who had demographic and laboratory data at baseline and at least 3 years of follow-up. FIB-4 scores were analyzed to assess transitions between low-risk (2.67) categories over time. Competing risks for HCC and mortality were modeled to estimate the sub-distribution hazard ratios (SHRs). Results: Changes in FIB-4 scores over time provided superior predictive accuracy compared to one-time measurement. Individuals with persistent high FIB-4 (high-to-high group) had a 14-fold higher risk of developing HCC (adjusted SHR [aSHR] 13.91, 95% CI: 11.94–16.20) compared to those with stably low FIB-4 (low-to-low group), while those with improved scores (high-to-low and high-to-indeterminate groups) had a lower risk compared to the high-to-high group. Worsening FIB-4 scores, as shown in the low-to-indeterminate group (aSHR 2.22, 95% CI: 1.93–2.57 or the low-to-high group (aSHR 4.75, 95% CI: 3.38–6.68), were associated with progressively increased risks of HCC compared to the low-to-low group. In contrast, when compared to the high-to-high group, those with improved FIB-4 scores, including the high-to-indeterminate group (aSHR 0.41, 95% CI: 0.35–0.48) and the high-to-low group (aSHR 0.25, 95% CI: 0.15–0.42), exhibited reduced HCC risks. Conclusion: Serial FIB-4 measurements offer greater accuracy in identifying individuals at high risk for HCC in non-cirrhotic MASLD Asians with elevated liver enzymes, with HCC surveillance warranted in high-risk groups.
- 12 January 2026
- Published by S. Karger AG in Liver Cancer
- p. 1-12
Open AccessDynamic FIB-4 Score Changes and HCC Risk in Patients with MASLD and Elevated Liver Enzymes: A Nationwide Cohort Study
Introduction: Hepatocellular carcinoma (HCC) can develop in individuals with metabolic dysfunction-associated steatotic liver disease (MASLD) without cirrhosis, especially in those with elevated liver enzymes. However, there is currently no low-cost, scalable screening tool for this population. To address this need, we investigated the association between serial changes in FIB-4 (fibrosis-4) scores over a 3-year period and the risk of developing HCC in a large, diverse cohort of patients with MASLD without cirrhosis. Methods: This study utilized a nationwide cohort from the National Health Insurance Research Database (NHIRD), including 810,698 patients with MASLD who had demographic and laboratory data at baseline and at least 3 years of follow-up. FIB-4 scores were analyzed to assess transitions between low-risk (2.67) categories over time. Competing risks for HCC and mortality were modeled to estimate the sub-distribution hazard ratios (SHRs). Results: Changes in FIB-4 scores over time provided superior predictive accuracy compared to one-time measurement. Individuals with persistent high FIB-4 (high-to-high group) had a 14-fold higher risk of developing HCC (adjusted SHR [aSHR] 13.91, 95% CI: 11.94–16.20) compared to those with stably low FIB-4 (low-to-low group), while those with improved scores (high-to-low and high-to-indeterminate groups) had a lower risk compared to the high-to-high group. Worsening FIB-4 scores, as shown in the low-to-indeterminate group (aSHR 2.22, 95% CI: 1.93–2.57 or the low-to-high group (aSHR 4.75, 95% CI: 3.38–6.68), were associated with progressively increased risks of HCC compared to the low-to-low group. In contrast, when compared to the high-to-high group, those with improved FIB-4 scores, including the high-to-indeterminate group (aSHR 0.41, 95% CI: 0.35–0.48) and the high-to-low group (aSHR 0.25, 95% CI: 0.15–0.42), exhibited reduced HCC risks. Conclusion: Serial FIB-4 measurements offer greater accuracy in identifying individuals at high risk for HCC in non-cirrhotic MASLD Asians with elevated liver enzymes, with HCC surveillance warranted in high-risk groups.
- 22 March 2023
- Published by S. Karger AG in Dermatology
- Vol. 239 (4) , 635-645
Risk of Psychiatric Disorders in Patients with Psoriasis Prescribed Acitretin versus Disease-Modifying Antirheumatic Drugs: A Nationwide Matched Cohort Study
Background: Acitretin has been linked to the development of psychiatric disturbance. Objectives: The aim of this study was to assess the psychiatric hazards in patients with psoriasis prescribed acitretin compared with those prescribed disease-modifying antirheumatic drugs (DMARDs). Methods: This is a nationwide matched cohort study. From Taiwan’s National Health Insurance Research Database, adult patients with psoriasis between 1997 and 2013 were screened. Patients prescribed acitretin for at least 30 days per year on average (acitretin cohort) were matched 1:2 with those prescribed DMARDs for at least 30 days per year on average (reference cohort), by means of age, gender, and psoriasis duration. Patients prescribed medication of the corresponding cohort for more than 7 days during the observation period were excluded. Cumulative incidences of psychiatric disorders in both cohorts were plotted with the Kaplan-Meier method. The modified Cox regression models were constructed to estimate hazard ratios (HRs). Results: In total, 1,152 and 2,304 patients in the acitretin and the reference cohorts, respectively, were included. The 4-year cumulative incidence of overall psychiatric disorders (19.62% vs. 12.06%; p < 0.001), mood disorders (12.81% vs. 7.67%; p < 0.001), and psychosis (7.21% vs. 4.63%; p < 0.001) in the acitretin cohort was significantly higher than that in the reference cohort. Acitretin was independently associated with psychiatric disorders (HR 1.51, 95% confidence interval [CI] 1.23–1.85). The risk is more accentuated in the subgroups of comorbid chronic liver disease (HR 2.60, 95% CI: 1.56–4.33) or psoriatic arthritis (HR 3.23, 95% CI: 1.75–5.97). Other independent risk factors included insomnia, acute coronary syndrome, females, and age. Conclusions: Compared with DMARDs, acitretin was associated with higher hazards of psychiatric disorders among psoriasis patients.
- 22 March 2023
- Published by S. Karger AG in Dermatology
- Vol. 239 (4) , 635-645
Risk of Psychiatric Disorders in Patients with Psoriasis Prescribed Acitretin versus Disease-Modifying Antirheumatic Drugs: A Nationwide Matched Cohort Study
Background: Acitretin has been linked to the development of psychiatric disturbance. Objectives: The aim of this study was to assess the psychiatric hazards in patients with psoriasis prescribed acitretin compared with those prescribed disease-modifying antirheumatic drugs (DMARDs). Methods: This is a nationwide matched cohort study. From Taiwan’s National Health Insurance Research Database, adult patients with psoriasis between 1997 and 2013 were screened. Patients prescribed acitretin for at least 30 days per year on average (acitretin cohort) were matched 1:2 with those prescribed DMARDs for at least 30 days per year on average (reference cohort), by means of age, gender, and psoriasis duration. Patients prescribed medication of the corresponding cohort for more than 7 days during the observation period were excluded. Cumulative incidences of psychiatric disorders in both cohorts were plotted with the Kaplan-Meier method. The modified Cox regression models were constructed to estimate hazard ratios (HRs). Results: In total, 1,152 and 2,304 patients in the acitretin and the reference cohorts, respectively, were included. The 4-year cumulative incidence of overall psychiatric disorders (19.62% vs. 12.06%; p < 0.001), mood disorders (12.81% vs. 7.67%; p < 0.001), and psychosis (7.21% vs. 4.63%; p < 0.001) in the acitretin cohort was significantly higher than that in the reference cohort. Acitretin was independently associated with psychiatric disorders (HR 1.51, 95% confidence interval [CI] 1.23–1.85). The risk is more accentuated in the subgroups of comorbid chronic liver disease (HR 2.60, 95% CI: 1.56–4.33) or psoriatic arthritis (HR 3.23, 95% CI: 1.75–5.97). Other independent risk factors included insomnia, acute coronary syndrome, females, and age. Conclusions: Compared with DMARDs, acitretin was associated with higher hazards of psychiatric disorders among psoriasis patients.
- 30 October 2020
- Published by Wiley in The Journal of Dermatology
- Vol. 48 (2) , 168-174
Atopic dermatitis does not increase the risk of inflammatory bowel disease: A nationwide cohort study
Coexistence of inflammatory bowel disease (IBD) in atopic dermatitis (AD) patients has been reported. The long‐term risk of IBD in AD patients remains unclear. Our aim for the study is to examine the long‐term risk of IBD in AD patients. This is a nationwide cohort study. From the National Health Insurance Research Database of Taiwan (1997–2013), a total of 36 400 AD patients were identified and matched with 364 000 reference subjects without AD by age, sex and number of hospital visits. Demographic characteristics and comorbidities were compared. Cox proportional hazards regression analysis was conducted to examine the risk of IBD. The 16‐year cumulative incidences of IBD were 0.047% (95% confidence interval [CI], 0.040–0.054) and 0.047% (95% CI, 0.025–0.096) in non‐AD and AD cohorts, respectively (P = 0.973). There were 17 cases of IBD (0.05%), including 10 ulcerative colitis and seven Crohn’s disease, among AD patients compared with 169 IBD cases (0.05%) among controls (P > 0.999). Infections (adjusted hazard ratio [HR], 2.71; 95% CI, 1.96–3.95; P < 0.001) and age (adjusted HR, 1.03; 95% CI, 1.02–1.03; P < 0.001) were independently associated with IBD, after adjusting for major comorbidities and conducting multivariate analyses. AD was not associated with IBD development. In conclusion, AD is not independently associated with IBD development.
- 30 October 2020
- Published by Wiley in The Journal of Dermatology
- Vol. 48 (2) , 168-174
Atopic dermatitis does not increase the risk of inflammatory bowel disease: A nationwide cohort study
Coexistence of inflammatory bowel disease (IBD) in atopic dermatitis (AD) patients has been reported. The long‐term risk of IBD in AD patients remains unclear. Our aim for the study is to examine the long‐term risk of IBD in AD patients. This is a nationwide cohort study. From the National Health Insurance Research Database of Taiwan (1997–2013), a total of 36 400 AD patients were identified and matched with 364 000 reference subjects without AD by age, sex and number of hospital visits. Demographic characteristics and comorbidities were compared. Cox proportional hazards regression analysis was conducted to examine the risk of IBD. The 16‐year cumulative incidences of IBD were 0.047% (95% confidence interval [CI], 0.040–0.054) and 0.047% (95% CI, 0.025–0.096) in non‐AD and AD cohorts, respectively (P = 0.973). There were 17 cases of IBD (0.05%), including 10 ulcerative colitis and seven Crohn’s disease, among AD patients compared with 169 IBD cases (0.05%) among controls (P > 0.999). Infections (adjusted hazard ratio [HR], 2.71; 95% CI, 1.96–3.95; P < 0.001) and age (adjusted HR, 1.03; 95% CI, 1.02–1.03; P < 0.001) were independently associated with IBD, after adjusting for major comorbidities and conducting multivariate analyses. AD was not associated with IBD development. In conclusion, AD is not independently associated with IBD development.
- 1 May 2018
- Published by Elsevier in Gastroenterology
- Vol. 154 (6) , S-1128-1128
Sa1483 - Real-World Rates of Hepatitis B Surface Antigen (HBSAG) Seroclearance in Patients with Chronic Hepatitis B (CHB): A Systematic Review, Conventional Aggregated Data Meta-Analysis (ADMA) and Individual Patient Data Meta-Analysis (IPDMA)
- 1 May 2018
- Published by Elsevier in Gastroenterology
- Vol. 154 (6) , S-1128-1128
Sa1483 - Real-World Rates of Hepatitis B Surface Antigen (HBSAG) Seroclearance in Patients with Chronic Hepatitis B (CHB): A Systematic Review, Conventional Aggregated Data Meta-Analysis (ADMA) and Individual Patient Data Meta-Analysis (IPDMA)